Amneal to acquire substantially all of kashiv specialty pharmaceuticals

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (the “company”) (nyse:amrx) and kashiv biosciences llc (“kashiv”) today announced they have entered into a definitive agreement under which amneal pharmaceuticals llc (“amneal”), a wholly-owned subsidiary of the company, will acquire a 98% interest in kashiv specialty pharmaceuticals, llc (“kashiv specialty”), a wholly-owned subsidiary of kashiv focused on the development of complex generics, innovative drug delivery platforms and
AMRX Ratings Summary
AMRX Quant Ranking